Keveyis

Generic name: dichlorphenamide

Drug class: Carbonic anhydrase inhibitors

Dosage form: Tablets

Root of administration: Oral

Dose: Initiate at 50 mg once or twice daily; adjust based on individual response; minimum 50 mg daily, maximum 200 mg daily

Mechanism of action: Dichlorphenamide inhibits carbonic anhydrase, leading to decreased muscle excitability and reduced frequency of periodic paralysis episodes.

Drug usage cases:

• Primary hyperkalemic periodic paralysis
• Primary hypokalemic periodic paralysis
• Related variants of periodic paralysis

Drug contra indications:

• Severe breathing problems
• Liver disease
• Allergy to sulfa drugs
• Concurrent high-dose aspirin therapy

Side effects:

• Numbness or tingling
• Difficulty thinking and paying attention
• Changes in taste
• Confusion
• Leg cramps
• Constipation
• Irregular heartbeats
• Fluttering in the chest
• Increased thirst or urination
• Numbness or tingling
• Muscle weakness or limp feeling
• Signs of too much acid in the blood: irregular heartbeats, feeling tired, loss of appetite, trouble thinking, feeling short of breath

Warnings:

• May cause blurred vision and impair reactions; avoid driving or hazardous activities until effects are known
• Risk of accidental falls, especially in older adults or those on high doses
• Monitor for metabolic acidosis; may require dose adjustment or discontinuation if persistent
• Use caution in patients with electrolyte imbalances; monitor serum bicarbonate levels
• Potential for drug interactions; inform healthcare providers of all medications

Use during pregnancy or breastfeeding: Avoid use during pregnancy due to potential harm from metabolic acidosis. Safety during breastfeeding is not established; consult a healthcare provider for guidance.